ReviewACS omega2024
The Application of Biomaterials for the Vaccine, Treatment, and Detection of SARS-CoV-2.
Review in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 8 citations in OpenAlex.
- Formation and preliminary characterization of mercury-reactive immunoglobulin Y antibodies in laying hens using HgClVeterinary world · 2026Article
- Next-generation mucosal vaccines for respiratory viruses: Immunological correlates, platform design and clinical translation.World journal of virology · 2026Review
- Tailored Anti-miR Decorated Covalent Organic Framework Enables Electrochemical Detection of Salivary miRNAs for Mild Traumatic Brain Injury.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease-19 (COVID-19) pandemic has had a significant impact on human life worldwide since 2019. Specific vaccines and antiviral agents are the most effective means of preventing and treating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Additionally, antiviral protective equipment and early diagnosis also contribute to controlling the spread of COVID-19. The utilization of biomaterials in medicine and pharmaceuticals is crucial to ensure the positive impact of vaccines, antiviral agents, and protective equipment. In this review, we discuss the application of various types of biomaterials, including polymers, lipid nanoparticles, inorganic biomaterials, protein- or peptide-associated biomaterials, self-assembled biomaterials, and other biomaterials, for the vaccine, treatment, and prevention of COVID-19. Finally, we provide a perspective on future opportunities and challenges for developing biomaterials to combat other viral outbreaks and diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.